Long intergenic non-protein coding RNA 1089 (LINC01089)

Long intergenic non-protein coding RNA 1089 (LINC01089) is a highly conserved long non-coding RNA (lncRNA) mapping to chromosome 12 and functions as a tumor suppressor in human cancers, including breast cancer and non-small cell lung cancer[1][2]. LINC01089 is significantly downregulated in tumor tissues and cell lines, and low expression levels are associated with lymph node metastasis and poor prognosis. Functionally, LINC01089 inhibits cell proliferation, migration, and invasion, while promoting apoptosis and cell cycle arrest at G0/G1. Mechanistically, LINC01089 suppresses the canonical Wnt/β-catenin pathway by downregulating β-catenin transcription[1] and acts as a miR-27a sponge, thereby elevating SFRP1 levels and reducing epithelial–mesenchymal transition (EMT) in lung cancer[2]. Its tumor-suppressive effects highlight its potential as both a prognostic biomarker and a future therapeutic RNA-based target for metastasis inhibition in solid tumors. No direct pharmacological ligands or drugs currently target LINC01089, but it is under investigation as a biomarker and possible future RNA-targeted therapy candidate.

Other names

LIMTLong non-coding RNA inhibiting metastasisAK096174LncRNA inhibiting metastasis

LINC01089 is not a direct druggable protein or enzyme; it acts via RNA-based regulatory mechanisms. It inhibits the Wnt/β-catenin pathway through transcriptional repression of β-catenin. It also acts as a competitive endogenous RNA sponging miR-27a, thereby elevating SFRP1 and suppressing EMT and tumor progression.